PAK4 and osteosarcoma: Therefore, although there are limited reports on using PAK4 inhibition in the therapeutic approach to osteosarcoma, it is suggested that using an agent targeting PAK4 might be helpful for those in the poor prognostic group of osteosarcoma patients who express high levels of PAK4.